J3386 — Injection, etuvetidigene autotemcel, per treatment
J3386 is a HCPCS Level II code for injection, etuvetidigene autotemcel, per treatment. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for J3386
- Long descriptor
- Injection, etuvetidigene autotemcel, per treatment
- Short descriptor
- Etuvetidigene autotemecel
- Added
- July 1, 2026
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J3386
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J3386 is not quite right, the correct code is very often within a few positions of it.
- J3372Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mgterminated
- J3373Injection, vancomycin hydrochloride, 10 mg
- J3374Injection, vancomycin hydrochloride (mylan) not therapeutically equivalent to j3373, 10 mg
- J3375Injection, vancomycin hydrochloride (tyzavan), not therapeutically equivalent to j3373, 10 mg
- J3376Injection, vancomycin hcl (hikma), not therapeutically equivalent to j3373, 10 mg
- J3379Injection, valproate sodium, 5 mg
- J3380Injection, vedolizumab, intravenous, 1 mg
- J3385Injection, velaglucerase alfa, 100 units
- J3387Injection, elivaldogene autotemcel, per treatment
- J3389Topical administration, prademagene zamikeracel, per treatment
- J3391Injection, atidarsagene autotemcel, per treatment
- J3392Injection, exagamglogene autotemcel, per treatment
- J3393Injection, betibeglogene autotemcel, per treatment
- J3394Injection, lovotibeglogene autotemcel, per treatment
- J3396Injection, verteporfin, 0.1 mg
- J3397Injection, vestronidase alfa-vjbk, 1 mg
Questions about J3386
What is HCPCS code J3386?
J3386 is a HCPCS Level II code for injection, etuvetidigene autotemcel, per treatment. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J3386?
The CMS HCPCS file marks J3386 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J3386 paid under the physician fee schedule?
J3386 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).